Our Approach

A Partner for the Whole Early-Phase Journey

Accelsiors supports early-phase clinical development as part of a broader full-service clinical development model. We work with sponsors from early development strategy through to study design, regulatory preparation, site activation, clinical execution, and data delivery.

Our approach is built around integration — not handoffs. When we support an early-phase programme, the scientific, regulatory, and operational teams work as a single unit, ensuring that study design decisions are informed by execution realities, and that execution is guided by scientific intent.

This means:

 

Dose-Escalation-Studies

Clinical trial study design

Reflecting the pharmacology, the regulatory pathway, and the operational environment, not just protocol convention.

regulatory-and-ethical-compliance

Regulatory and ethical preparation

Supported by experienced regulatory professionals with knowledge of European regulatory frameworks, including pediatric regulatory considerations where relevant to the program, ensuring that CTA submissions and ethics approvals are built for efficiency and compliance.

clinical-development

PK/PD and biomarker integration

Embedded into study design from the outset, not added as an afterthought.

Data-Management-and-Analysis

Safety and tolerability assessment frameworks

Appropriate to the compound, the mechanism, and the study population, including age-adapted frameworks for pediatric studies.

future-early-phase-adaptive-ai

Dose escalation strategies

Grounded in quantitative pharmacology, pharmacometrics, and adaptive design principles.

study-design

Operational planning

That accounts for recruitment realism, site capability, data flow, and timeline integrity.

A practical advantage is that we support not only transition planning, but also the move into actual early clinical conduct through closely collaborating early-phase clinical research units across Europe. That helps sponsors match each study to the right setting, including healthy volunteer and patient-based pathways, while reducing handoff risk and preserving scientific integrity.